Cover Image
市場調查報告書

OpportunityAnalyzer:亨丁頓舞蹈症 - 市場機會分析及市場預測

OpportunityAnalyzer: Huntington's Disease - Opportunity Analysis and Forecast to 2024

出版商 GlobalData 商品編碼 365813
出版日期 內容資訊 英文 250 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:亨丁頓舞蹈症 - 市場機會分析及市場預測 OpportunityAnalyzer: Huntington's Disease - Opportunity Analysis and Forecast to 2024
出版日期: 2016年05月03日 內容資訊: 英文 250 Pages
簡介

本報告提供亨丁頓舞蹈症治療藥的市場調查,疾病概要,風險因素、併發症,發病診斷數的預測,目前治療選擇,領導品牌簡介,未滿足需求與市場機會分析,R&D策略分析,開發平台趨勢與主要候補藥的基準,競爭環境,主要地區、國家的10年銷售額預測等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • QoL
  • 症狀
  • 診斷、疾病監測

第4章 流行病學

  • 疾病背景
  • 風險因素、併發症
  • 全球趨勢
  • 預測手法
  • 流行病學的預測
    • 發病診斷數
    • 發病診斷數:各發病年齡
    • 青年性亨丁頓舞蹈症的成人診斷數
  • 討論
    • 流行病學的預測相關考察
    • 分析上的規定
    • 分析的有益性

第5章 目前治療選擇

  • 概要
    • 抗精神病藥
    • 抗憂鬱藥
    • 苯重氮基鹽
    • 抗痙攣藥
    • 抗帕金森藥
    • A型肉毒桿菌
  • 產品簡介:領導品牌
    • Xenazine (Tetrabenazine)
    • Tiapride

第6章 未滿足需求與市場機會分析

  • 概要
  • 緩解疾病藥
  • 有效的認知功能改善藥
  • 對症療法的改良
  • 生物標記的鑑定
  • 新的病因查明
  • 更全面的治療指南
  • 新的製劑
    • 未滿足需求
    • 差距分析
    • 市場機會

第7章 R&D策略

  • 概要
    • 緩解疾病藥
    • 臨床性對策和生物標記的鑑定
  • 臨床試驗設計
    • 有效性評估項目
    • 病例組入
    • 施行地點
    • 臨床試驗類型

第8章 開發平台評估

  • 概要
    • SD-809(Deutetrabenazine)
    • Pridopidine Hydrochloride
    • RP103(Cysteamine Bitartrate)
    • PF-02545920
    • Laquinimod
    • PBT2
  • 開發初期階段的創新方法
    • VX-15
    • IONIS-HTTRx

第9章 開發平台評估分析

  • 主要開發平台藥物的臨床性基準
  • 主要開發平台藥物的商業性基準
  • 競爭分析
  • top line10年預測
    • 美國
    • 歐盟5國
    • 日本

第10章 附錄

圖表

目錄
Product Code: GDHC056POA

Huntington's Disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired motor control, cognitive dysfunction, behavioral changes, and mood disorders. Approved treatments for HD across the 7MM are extremely limited, consisting of only two symptomatic treatments, tetrabenazine and tiapride, which are both approved for the treatment of HD-associated chorea. Other treatment options contributing to the HD market are off-label symptomatic drugs, many of which are widely genericized throughout the 7MM. Four late-stage pipeline drugs, two symptomatic treatments (SD-809 and pridopidine) and two potential DMDs (RP103 and PBT2) are expected to launch in the US and 5EU markets during the forecast period, and will be a source of significant growth in the HD market. It is anticipated that SD-809 and pridopidine will also launch in Japan within the forecast period.

Highlights

Key Questions Answered

  • The HD market has been dominated by tetrabenazine and tiapride (approved in Germany, Italy, and Spain; off-label in France and Japan) for many years, with little approved therapeutic options available in the 7MM. New classes of drugs are anticipated to reach the market within the forecast period. How will these change the market overall during the forecast period? Will tetrabenazine maintain market dominance in 2024?
  • The current late stage HD pipeline is varied, with first-in-class drugs in development with innovative modes of action. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this chronically underserved market? Will these fulfil any unmet needs?

Key Findings

  • The main driver of growth in the HD market will be the introduction of premium-priced disease-modifying drugs and improved symptomatic therapies over the forecast period. The launch of these treatments will act as a stimulant for growth in this chronically underserved market.
  • Significant barriers to growth in the HD market will be the high cost of novel treatments and potential issues surrounding reimbursement, which will limit the use of more expensive drugs. Patients who have an acceptable level of symptomatic control with currently marketed drugs could result in limited treatment costs for HD.
  • The arrival of new therapies across the 7MM will increase treatment rates and provide alternative options for many patients.
  • The largest unmet needs in the HD market are the development of efficacious disease-modifying drugs and symptomatic treatments. In addition, the identification of a robust HD biomarker for monitoring disease progression, as well as determining the effects of therapeutic interventions, is a significant unmet need in this field.

Scope

  • Overview of HD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HD market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the HD therapeutics market.
  • Pipeline analysis: focus on the six late-stage pipeline HD drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global HD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global HD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HD therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global HD therapeutics market from 2014-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Quality of Life
  • 3.3. Symptoms
  • 3.4. Diagnosis and Disease Monitoring

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Complications
  • 4.3. Global Trends
    • 4.3.1. Diagnosed Prevalence of HD-7MM
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of HD (2014-2024)
    • 4.5.1. Diagnosed Prevalent Cases
    • 4.5.2. Diagnosed Prevalent Cases of HD by Age at Onset
    • 4.5.3. Diagnosed Prevalent Cases of Adults with Juvenile-Onset HD that Progressed to Adulthood, Ages ≥20 Years
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Overview
    • 5.1.1. Antipsychotic Drugs
    • 5.1.2. Antidepressant Drugs
    • 5.1.3. Benzodiazepines
    • 5.1.4. Anticonvulsant Drugs
    • 5.1.5. Antiparkinson Drugs
    • 5.1.6. Botulinum Toxin Type A
  • 5.2. Product Profiles-Major Brands
    • 5.2.1. Xenazine (Tetrabenazine)
    • 5.2.2. Tiapride

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Disease-Modifying Drugs
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Efficacious Cognitive Enhancers
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Improved Symptomatic Treatments
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Identification of Disease Biomarker
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Increased Knowledge of HD Pathogenesis
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. More Comprehensive Treatment Guidelines
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity
  • 6.8. Novel Formulations
    • 6.8.1. Unmet Need
    • 6.8.2. Gap Analysis
    • 6.8.3. Opportunity

7. R&D Strategies

  • 7.1. Overview
    • 7.1.1. Disease-Modifying Drugs
    • 7.1.2. Clinical Measures and Biomarker Identification
  • 7.2. Clinical Trial Design
    • 7.2.1. Efficacy Endpoints
    • 7.2.2. Patient Inclusion
    • 7.2.3. Trial Locations
    • 7.2.4. Type of Clinical Trial

8. Pipeline Assessment

  • 8.1. Overview
    • 8.1.1. SD-809(Deutetrabenazine)
    • 8.1.2. Pridopidine Hydrochloride
    • 8.1.3. RP103(Cysteamine Bitartrate)
    • 8.1.4. PF-02545920
    • 8.1.5. Laquinimod
    • 8.1.6. PBT2
  • 8.2. Innovative Early-Stage Approaches
    • 8.2.1. VX-15
    • 8.2.2. IONIS-HTTRx

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line 10-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU
    • 9.4.3. Japan

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed HD Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline Agents
  • 10.5. Primary Research
    • 10.5.1. Physicians and Specialists Included in this Study
    • 10.5.2. Online Survey of High-Prescribing Physicians
  • 10.6. About the Authors
    • 10.6.1. Author
    • 10.6.2. Reviewer
    • 10.6.3. Therapy Area Director
    • 10.6.4. Epidemiologist
    • 10.6.5. Global Director of Therapy Analysis and Epidemiology
    • 10.6.6. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Common Symptoms of HD
  • Table 2: The UHDRS Total Functional Capacity Scale
  • Table 3: The Shoulson-Fahn Huntington's Disease Severity Scale
  • Table 4: Risk Factors and Complications for HD
  • Table 5: 7MM Estimates for the Diagnosed Prevalence of HD
  • Table 6: 7MM, Sources of Epidemiological Data Used for the Forecast of HD Diagnosed Prevalent Cases
  • Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast of JHD Diagnosed Prevalent Cases
  • Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast of HD Diagnosed Prevalent Cases by Age at Onset
  • Table 9: 7MM, Diagnosed Prevalent Cases of HD, All Ages, Both Sexes, N, 2014-2024
  • Table 10: 7MM, Diagnosed Prevalent Cases of HD by Age Group, Both Sexes, N (%), 2014
  • Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of HD, All Ages, N (%), 2014
  • Table 12: 7MM, Diagnosed Prevalent Cases of JHD, Age <20 Years, Both Sexes, N, 2014-2024
  • Table 13: 7MM, Age-Specific Diagnosed Prevalent Cases of JHD, Both Sexes, N (%), 2014
  • Table 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of JHD, Age <20 Years, N (%), 2014
  • Table 15: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset HD that Progressed to Adulthood, Age ≥20 Years, Both Sexes, N, 2014-2024
  • Table 16: Leading Treatments for HD, 2016
  • Table 17: Antipsychotics SWOT Analysis, 2016
  • Table 18: Antidepressants SWOT Analysis, 2016
  • Table 19: Benzodiazepines SWOT Analysis, 2016
  • Table 20: Anticonvulsants SWOT Analysis, 2016
  • Table 21: Antiparkinson Drugs SWOT Analysis, 2016
  • Table 22: Botulinum Toxin Type A SWOT Analysis, 2016
  • Table 23: Product Profile-Xenazine
  • Table 24: Xenazine SWOT Analysis, 2016
  • Table 25: Product Profile-Tiapride
  • Table 26: Tiapride SWOT Analysis, 2016
  • Table 27: Overall Unmet Needs-Current Level of Attainment
  • Table 28: HD-Late-Stage Pipeline, 2016
  • Table 29: Product Profile-SD-809
  • Table 30: Summary of Treatment Effects of SD-809 on the Motor Endpoints in the FIRST-HD Clinical Trial
  • Table 31: Summary of Treatment Effects of SD-809 on the Secondary Endpoints in the FIRST-HD Clinical Trial
  • Table 32: SD-809 SWOT Analysis, 2016
  • Table 33: Product Profile-Pridopidine
  • Table 34: Summary of Adverse Events in the MermaiHD Clinical Trial of Pridopidine
  • Table 35: Summary of the Most Common Adverse Events in the HART Clinical Trial of Pridopidine
  • Table 36: Pridopidine SWOT Analysis, 2016
  • Table 37: Product Profile-RP103
  • Table 38: RP103 SWOT Analysis, 2016
  • Table 39: Product Profile-PF-02545920
  • Table 40: PF-02545920 SWOT Analysis, 2016
  • Table 41: Product Profile-Laquinimod
  • Table 42: Laquinimod SWOT Analysis, 2016
  • Table 43: Product Profile-PBT2
  • Table 44: Summary of the Adverse Events in the REACH2HD Clinical Trial of PBT2
  • Table 45: PBT2 SWOT Analysis, 2016
  • Table 46: Early-Stage Pipeline Products in HD
  • Table 47: Clinical Benchmark of Key Pipeline Drugs-HD
  • Table 48: Commercial Benchmark of Key Pipeline Drugs-HD
  • Table 49: Top-Line Sales Forecast ($m) for HD, 2014-2024
  • Table 50: Key Events Impacting Sales for HD, 2014-2024
  • Table 51: HD Market-Drivers and Barriers, 2014-2024
  • Table 52: Key Launch Dates
  • Table 53: Key Patent Expiries
  • Table 54: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Cortico-basal Ganglia Network Indicating the Direct and Indirect Pathways
  • Figure 2: 7MM, Diagnosed Prevalent Cases of HD, All Ages, Both Sexes, N, 2014-2024
  • Figure 3: 7MM, Diagnosed Prevalent Cases of HD by Age Group, Both Sexes, N, 2014
  • Figure 4: 7MM, Diagnosed Prevalent Cases of HD by Sex, All Ages, N, 2014
  • Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of HD (%) by Sex, All Ages, 2014
  • Figure 6: 7MM, Diagnosed Prevalent Cases of JHD, Age <20 Years, Both Sexes, N, 2014-2024
  • Figure 7: 7MM, Diagnosed Prevalent Cases of JHD by Age Group, Both Sexes, N
  • Figure 8: 7MM, Diagnosed Prevalent Cases of JHD by Sex, Age <20 Years, N, 2014
  • Figure 9: 7MM, Diagnosed Prevalent Cases of HD by Age at Onset, Both Sexes, N, 2014
  • Figure 10: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset HD that Progressed to Adulthood, Age ≥20 Years, Both Sexes, N, 2014
  • Figure 11: Competitive Assessment of Marketed and Late-Stage Pipeline HD Drugs, 2014-2024
  • Figure 12: Sales for HD by Region, 2014-2024
Back to Top